Vortioxetine 10 mg/day + Vortioxetine 20 mg/day + Fluoxetine 20 mg/day
Phase 3Completed 2 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Depressive Disorder, Major
Conditions
Depressive Disorder, Major
Trial Timeline
May 1, 2016 → Jul 30, 2019
NCT ID
NCT02709746About Vortioxetine 10 mg/day + Vortioxetine 20 mg/day + Fluoxetine 20 mg/day
Vortioxetine 10 mg/day + Vortioxetine 20 mg/day + Fluoxetine 20 mg/day is a phase 3 stage product being developed by Lundbeck for Depressive Disorder, Major. The current trial status is completed. This product is registered under clinical trial identifier NCT02709746. Target conditions include Depressive Disorder, Major.
What happened to similar drugs?
20 of 20 similar drugs in Depressive Disorder, Major were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02709746 | Phase 3 | Completed |
Competing Products
20 competing products in Depressive Disorder, Major
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| duloxetine | Eli Lilly | Pre-clinical | 26 |
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 26 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 29 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 40 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 43 |
| Duloxetine Hydrochloride | Shionogi | Phase 3 | 32 |
| Duloxetine Hydrochloride + Placebo | Shionogi | Phase 3 | 40 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 42 |